Vyne Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Vyne Therapeutics Inc Unternehmen

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc Informationen



BörsenkürzelVYNE

Name des UnternehmensVyne Therapeutics Inc

IPO-datumJan 25, 2018

CEODomzalski (David)

Anzahl der mitarbeiter13

WertpapierartOrdinary Share

GeschäftsjahresendeJan 25

Addresse685 Route 202/206 N., Suite 301

StadtBRIDGEWATER

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl08807

Telefon18007757936

Websitehttps://vynetherapeutics.com/

BörsenkürzelVYNE

IPO-datumJan 25, 2018

CEODomzalski (David)

Führungskräfte von Vyne Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

104.92K

-7858.00%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

51.16K

-3579.00%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

41.85K

-2448.00%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Sharon Barbari

Independent Director

--

Mr. Patrick G. Lepore

Lead Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

104.92K

-7858.00%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

51.16K

-3579.00%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

41.85K

-2448.00%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2024

FY2023

FY2022

FY2021

FY2020

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Royalty revenues

501.00K

0.00%

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Royalty revenues

501.00K

0.00%

Aktionärsstatistik

Aktualisiert: Sat, Feb 7

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

Andere

88.75%

Aktionäre

Anteil

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

Andere

88.75%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

8.46%

Investment Advisor

3.54%

Corporation

3.35%

Investment Advisor/Hedge Fund

2.27%

Individual Investor

1.23%

Research Firm

0.45%

Andere

80.70%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

88

4.85M

14.58%

-6.84M

2025Q3

84

8.51M

25.77%

-898.65K

2025Q2

84

9.46M

56.76%

-1.30M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Access Industries, Inc.

1.12M

3.35%

--

Oct 15, 2025

Baker Bros. Advisors LP

851.35K

2.56%

+851.35K

--

Sep 30, 2025

Delaware Street Capital, L.L.C.

696.47K

2.09%

--

Sep 30, 2024

Acorn Capital Advisors, LLC

586.57K

1.76%

-150.00K

-20.36%

Sep 30, 2025

Shay Capital LLC

492.58K

1.48%

+492.58K

--

Sep 30, 2025

Acadian Asset Management LLC

446.41K

1.34%

+424.00K

+1891.32%

Sep 30, 2025

The Vanguard Group, Inc.

190.38K

0.57%

-305.91K

-61.64%

Sep 30, 2025

Ikarian Capital LLC

290.00K

0.87%

--

Sep 30, 2025

Two Sigma Investments, LP

277.39K

0.83%

+277.39K

--

Sep 30, 2025

Domzalski (David T)

152.86K

0.46%

-12.68K

-7.66%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Datum

Ex-Dividendentag

Art

Verhältnis

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1